We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for tafenoquine (GlaxoSmithKline Australia Pty Ltd)
Active ingredients
tafenoquine
Date of review outcome
Lapse date
Type
Orphan drug
Indication
indicated for the radical cure (prevention of relapse) ofPIasmodium vivax (P. vivax) malaria in patients aged 6 months and older (weighing >. 5 kg) who are receiving appropriate antimalarial therapy for the acute P.vivax infection